Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2016 16:02 ET | Source: VBL Therapeutics

Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data

VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...